• Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. 

  Mensah, AA; Cascione, L; Gaudio, E; Tarantelli, C; Bomben, R; Bernasconi, E; Zito, D; Lampis, A; Hahne, JC; Rinaldi, A; Stathis, A; Zucca, E; Kwee, I; Gattei, V; Valeri, N; Riveiro, ME; Bertoni, F (2018-08-03)

  Aberrant changes in microRNA expression contribute to lymphomagenesis. Bromodomain and extra-terminal domain inhibitors like OTX015 (MK-8628, birabresib) have demonstrated preclinical and clinical activity in haematological ...
• Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. 

  Cristofanilli, M; DeMichele, A; Giorgetti, C; Turner, NC; Slamon, DJ; Im, S-A; Masuda, N; Verma, S; Loi, S; Colleoni, M; Theall, KP; Huang, X; Liu, Y; Bartlett, CH (2018-10-08)

  BACKGROUND: The addition of palbociclib to fulvestrant improved clinical outcomes over placebo-fulvestrant in endocrine-pretreated metastatic breast cancer (MBC) patients in PALOMA-3. Here, we examined factors predictive ...
• A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. 

  Bødker, JS; Brøndum, RF; Schmitz, A; Schönherz, AA; Jespersen, DS; Sønderkær, M; Vesteghem, C; Due, H; Nørgaard, CH; Perez-Andres, M; Samur, MK; Davies, F; Walker, B; Pawlyn, C; Kaiser, M; Johnson, D; Bertsch, U; Broyl, A; van Duin, M; Shah, R; Johansen, P; Nørgaard, MA; Samworth, RJ; Sonneveld, P; Goldschmidt, H; Morgan, GJ; Orfao, A; Munshi, N; Johnson, HE; El-Galaly, T; Dybkær, K; Bøgsted, M (2018-09-25)

  Despite the recent progress in treatment of multiple myeloma (MM), it is still an incurable malignant disease, and we are therefore in need of new risk stratification tools that can help us to understand the disease and ...
• Detection of circulating tumour cell clusters in human glioblastoma. 

  Krol, I; Castro-Giner, F; Maurer, M; Gkountela, S; Szczerba, BM; Scherrer, R; Coleman, N; Carreira, S; Bachmann, F; Anderson, S; Engelhardt, M; Lane, H; Evans, TRJ; Plummer, R; Kristeleit, R; Lopez, J; Aceto, N

  Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating tumour cells (CTCs) are sporadically found in GBM patients, yet it is unclear whether multicellular ...
• RB1 Heterogeneity in Advanced Metastatic Castration Resistant Prostate Cancer. 

  Nava Rodrigues, D; Casiraghi, N; Romanel, A; Crespo, M; Miranda, S; Rescigno, P; Figueiredo, I; Riisnaes, R; Carreira, S; Sumanasuriya, S; Gasperini, P; Sharp, A; Mateo, J; Mackay, A; McNair, C; Schiewer, MJ; Knudsen, KE; Boysen, G; Demichelis, F; de Bono, JS (2018-09-26)

  PURPOSE: Metastatic castration resistant prostate cancer (mCRPC) is a lethal but clinically heterogeneous disease, with patients having variable benefit from endocrine and cytotoxic treatments. Intra-patient genomic ...

View more